Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Jeff Goater will present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:55 a.m. EDT. The presentation will cover Surface's lead programs, SRF617 targeting CD39, and SRF388 targeting IL-27, along with the emerging preclinical pipeline including SRF813 targeting CD112R (PVRIG). Live audio and archived webcasts will be available on the company's investor relations website.

Surface is focused on developing next-generation immunotherapies aimed at achieving sustained anti-tumor responses.

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, will present at the upcoming Wedbush PacGrow Healthcare Virtual Conference on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging preclinical pipeline, including SRF813 (targeting CD112R, also known as PVRIG).

The presentation will take place virtually on Tuesday, August 11, 2020 at 10:55 a.m. EDT. The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website: investors.surfaceoncology.com.

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397

FAQ

What is Surface Oncology presenting at the Wedbush PacGrow Healthcare Virtual Conference?

Surface Oncology will present its lead programs SRF617 and SRF388, and discuss its preclinical pipeline including SRF813.

When will Jeff Goater's presentation take place?

Jeff Goater's presentation is scheduled for August 11, 2020, at 10:55 a.m. EDT.

How can I access the presentation by Surface Oncology?

The presentation can be accessed live and as an archived webcast on Surface Oncology's investor relations website.

What are the key targets of Surface Oncology's lead programs?

Surface's lead programs target CD39 (SRF617) and IL-27 (SRF388).

What does Surface Oncology's preclinical pipeline include?

The preclinical pipeline includes SRF813 targeting CD112R, also known as PVRIG.